Wendell Helveston, MD
Neurology · Jackson, MSNPI 1881607158
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $702,511 of the $883,254 with a category attached, or 79.5%. It is spread thinly across 60 manufacturers, the largest accounting for just 23.4%. Among neurology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,486 payments — averaging $355.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$207K
- AbbVie$169K
- Biogen$82K
- Amgen$69K
- Jazz Pharmaceuticals Inc.$65K
- SK Life Science, Inc.$62K
- plus $229K from 54 others
Across 1 payment — averaging $940.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$940
What the payments were for
- Consulting fees$91,67410%
- Speaking & faculty fees$702,51180%
- Travel & lodging$47,3325%
- Food & beverage$41,2495%
- Education$4880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$883,254 in reported general payments places this provider in the 95th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 147 | $739,391 |
| EpidiolexCannabidiol (Cbd) | 74 | $403,599 |
| XcopriCenobamate | 165 | $256,138 |
| IngrezzaValbenazine Tosylate | 15 | $180,302 |
| Nurtec OdtRimegepant Sulfate | 102 | $123,061 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 21 | $114,826 |
| UbrelvyUbrogepant | 96 | $107,850 |
| QuliptaAtogepant | 71 | $92,658 |
| ZonegranZonisamide | 14 | $83,151 |
| FycompaPerampanel | 46 | $59,304 |
| Aimovig AutoinjectorErenumab-Aooe | 73 | $56,975 |
| Emgality PenGalcanezumab-Gnlm | 43 | $42,619 |
| BriviactBrivaracetam | 18 | $37,878 |
| AptiomEslicarbazepine Acetate | 27 | $37,747 |
| LamictalLamotrigine | 12 | $35,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,349 | $739,391147 claims |
| SK Life Science, Inc.Xcopri | $62,393 | $256,138165 claims |
| AbbVieUbrelvy, Qulipta | $168,859 | $200,508167 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $858 | $180,30215 claims |
| PfizerNurtec Odt, Dilantin, Eliquis | $5,909 | $136,055139 claims |
| Eisai Inc.Fycompa | $207,026 | $59,30446 claims |
| UCB, Inc.Briviact, Nayzilam | $27,705 | $48,01830 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $2,680 | $37,74727 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $92 | $30,75317 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $303 | $22,39721 claims |
| Upsher-smith Laboratories LLCTopiramate | $84 | $2,718220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 neurology providers in Mississippi.
Other neurology in Jackson
- Ruth FredericksJackson$943K
- Rajesh SharmaJackson$152K
- Patrick WeldonJackson$85K
- Riichi OtaJackson$53K
- Mitchell MyersJackson$43K
- Tiffany ScarffJackson$29K
- Derek LetortJackson$25K
- Shreyas GangadharaJackson$20K
- Juebin HuangJackson$20K
- David McHenryJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.